Understand the source comparison
Glow Stack Peptide Safety: Clinical vs Real-World Comparison
Nicotinamide Riboside 250–1,000mg daily 1,000–2,000mg daily 3.2% (mild GI, flushing) Higher doses not systematically studied; methylation pathway impact unclear beyond 12 weeks Well-tolerated at trial doses; supra-therapeutic use lacks long-term data Glycine 3
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Nicotinamide Riboside
- 250–1,000mg daily
- 1,000–2,000mg daily
- 3.2% (mild GI, flushing)
- Higher doses not systematically studied; methylation pathway impact unclear beyond 12 weeks
- Well-tolerated at trial doses; supra-therapeutic use lacks long-term data
- Glycine
- 3–15g daily
- 5–15g daily
- 1.8% (transient nausea)
- GRAS status; renal clearance handles excess; osmotic GI effects above 10g
- Exceptionally safe; titrate slowly to avoid GI upset
- Reduced L-Glutathione
- 500–1,000mg daily
- 2.8% (bloating, aftertaste)
- Poor oral bioavailability limits systemic effect; liposomal forms improve absorption but cost more
- Minimal side effects; efficacy limited by first-pass metabolism
- The comparison underscores a consistent theme: individual peptides are well-tolerated within studied dose ranges. The unknowns emerge when doses exceed trial parameters and peptides are combined without pharmacokinetic oversight.